Abstract
Although the usage of mesenchymal stromal cells (MSC) as therapy for Graft versus Host Disease (GvHD) is constantly increasing, studies on MSC efficacy have been scarcely corroborated by biological analysis of patient response to cell infusion. We report the immunological monitoring of 9 patients with steroid-refractory GvHD, receiving multiple doses of MSCs. GvHD presented as acute in 5 cases and chronic in 4 cases. After MSC therapy, 2 patients showed complete response (CR), 4 patients showed partial response (PR) whereas 3 patients did not respond (NR) to MSC infusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
